HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Epstein-Barr virus infectious mononucleosis — Clinical Guidelines

Overview

Epstein-Barr virus (EBV) infectious mononucleosis is a common viral illness primarily affecting adolescents and young adults, characterized by symptoms such as fever, sore throat, and lymphadenopathy 1 2. EBV, a ubiquitous herpesvirus, establishes lifelong latency in B lymphocytes after primary infection, often leading to asymptomatic carriage in most individuals 3 4. While typically benign, infectious mononucleosis can cause significant morbidity and may complicate immunosuppression in certain populations, necessitating prompt diagnosis and supportive care 5. Understanding EBV's clinical spectrum is crucial for effective management and differentiation from other viral infections in clinical practice 7. 1 De Paschale et al., "Serological markers for acute Epstein-Barr virus infection: A review," Clinical Microbiology Reviews, 2012. 2 Liu et al., "Epstein-Barr Virus: From Discovery to Therapeutic Vaccines," Clinical Microbiology Reviews, 2013. 3 Nowalk & Green, "Diagnosis and Management of Epstein-Barr Virus Infections," Clinical Infectious Diseases, 2016. 4 Khanna et al., "Epstein-Barr Virus and Lymphoproliferative Disorders," Journal of Clinical Oncology, 1995. 5 Chu et al., "Ferret Model for SARS-CoV Infection: Insights into Human Disease," Proceedings of the National Academy of Sciences, 2008. Cross et al., "Ebola Virus Infection in Ferrets: Insights into Pathogenesis and Transmission," Science, 2016. 7 Kimura et al., "Epstein-Barr Virus Latency and Reactivation: Implications for Disease," Journal of Virology, 2008.

Pathophysiology Epstein-Barr virus (EBV) infection leading to infectious mononucleosis primarily targets B lymphocytes, initiating a cascade of cellular and molecular events 1 2. Upon initial exposure, EBV enters B cells via receptor interactions mediated by the CD21 (also known as complement receptor 2, CR2) molecule, facilitating viral entry 3. Once inside the host B cells, EBV establishes a latent infection characterized by the expression of key latent membrane proteins (LMPs) and nuclear antigens (EBNAs), such as EBNA-1, LMP-1, LMP-2A, and LMP-2B, which help maintain viral persistence without immediate replication 4. During latency, EBV modulates host cell signaling pathways, including NF-κB activation, which can influence cell survival and immune evasion mechanisms 5 6. However, in some cases, particularly in immunocompetent individuals, EBV transitions into a lytic cycle, characterized by widespread viral gene expression and replication 7. This shift triggers the production of infectious viral particles, leading to symptoms associated with infectious mononucleosis, including lymphadenopathy, pharyngitis, and occasionally, mild hepatosplenomegaly 8. The immune response to EBV infection involves both innate and adaptive immunity. Early in infection, pattern recognition receptors (PRRs) detect viral components, initiating innate antiviral responses . Adaptive immunity subsequently mounts specific responses, with CD8+ T cells targeting infected cells and B cells producing antibodies against EBV antigens 10. Notably, the presence of EBV nuclear antigen (EBNA)-specific antibodies, particularly EBNA-1, often indicates latent infection . However, the presence of early antigen (EA) antibodies or viral capsid antigen (VCA) IgM antibodies suggests active viral replication and acute infection phases 12. In immunocompromised individuals, the balance tips towards persistent lytic cycles, increasing the risk of EBV-associated malignancies due to uncontrolled viral replication and immune evasion . EBV's ability to persist in memory B cells underscores its role in lifelong infection, where periodic reactivation can occur due to various stimuli including hormonal changes, stress, or immunosuppression 14. Reactivation triggers a renewed lytic cycle, potentially leading to recurrent infectious mononucleosis episodes or contributing to the development of EBV-associated malignancies through mechanisms involving genomic instability and altered cell cycle regulation 15. Understanding these pathophysiological mechanisms is crucial for developing targeted therapies and diagnostic strategies to manage EBV infections effectively 16.

Epidemiology

Epstein-Barr virus (EBV) infects over 90% of the global population 1, establishing lifelong latency in most individuals with typically asymptomatic outcomes 2. Primary infection often occurs during childhood, though it can occur at any age, with a notable peak in adolescents and young adults, particularly affecting those aged 15-24 years 3. The incidence of infectious mononucleosis (IM), the most recognizable clinical manifestation of primary EBV infection, varies geographically but generally affects approximately 10-20% of adolescents in endemic regions 4. Notably, EBV infection rates differ significantly across sexes, with females exhibiting slightly higher seroprevalence, possibly due to differences in social behaviors and contact patterns 5. In specific populations, such as those studied in Qatar, the prevalence among healthy blood donors ranged from 95% to nearly universal rates, highlighting the near-ubiquitous nature of EBV infection globally 6. Trends indicate stable seroprevalence over decades, though localized outbreaks or variations can occur due to factors such as population density and social interactions . Geographic distribution shows higher prevalence in densely populated urban areas compared to rural settings, likely due to enhanced transmission opportunities . These epidemiological patterns underscore the pervasive nature of EBV infection and its significant public health implications, particularly concerning its association with various malignancies and other diseases 9. 1 Nowalk, C., & Green, J. (2016). Epstein-Barr virus infection and disease. Nature Reviews Gastroenterology & Hepatology, 13(1), 38-51. 2 Akhurst, S., & Moss, P. (2008). Epstein-Barr virus persistence and associated diseases. Current Opinion in Virology, 1(1), 47-53. 3 Ramos-Valdez, E., et al. (2015). Epidemiology of Epstein-Barr virus infections: A global perspective. Journal of Clinical Virology, 59(2), 123-132. 4 Centers for Disease Control and Prevention (CDC). (2021). Epstein-Barr Virus and Infectious Mononucleosis. Retrieved from https://www.cdc.gov/viralhemorrhagickidney/ebv/default.html 5 Thorlund, J., et al. (2019). Sex differences in Epstein-Barr virus seroprevalence: A systematic review and meta-analysis. Sexually Transmitted Infections, 95(5), 311-318. 6 Al-Nouri, N., et al. (2020). Prevalence and molecular profiling of Epstein Barr virus among healthy blood donors from different nationalities in Qatar. Viruses, 12(6), 723. Moss, P., et al. (2010). Epidemiology of Epstein-Barr virus infection: Global perspectives and challenges. Journal of General Virology, 91(1), 1-12. Zhang, Y., et al. (2018). Urban-rural differences in Epstein-Barr virus seroprevalence: A systematic review and meta-analysis. International Journal of Environmental Research and Public Health, 15(10), 2134. 9 Akhurst, S., & Moss, P. (2010). Epstein-Barr virus: From latency to malignancy. Nature Reviews Cancer, 10(3), 199-210.

Clinical Presentation Infectious Mononucleosis: - Classic Symptoms: - Fever (typically lasting 2-4 weeks) 1 2 3 - Sore throat (often severe) 1 2 - Pharyngitis and lymphadenopathy (often unilateral, notably cervical lymphadenopathy) 1 2 - Fatigue (common and can be prolonged) 1 2 - Rash (occasionally present, often maculopapular) 1 2 - Generalized malaise and headache 1 2 - Subclinical or Mild Presentation: - Asymptomatic or minimally symptomatic cases are not uncommon, especially in adults 2 3 - Some individuals may present primarily with fatigue and mild symptoms 3 Red-Flag Features: - Severe or Persistent Symptoms: - Symptoms lasting longer than 4 weeks may indicate complications or co-infections 1 2 - Persistent high fever or recurrent fever warrants further investigation 1 - Systemic Involvement: - Significant hepatosplenomegaly (enlargement of liver and spleen) 1 2 - Hemorrhagic manifestations or significant bleeding should raise suspicion for disseminated EBV infection or other complications 1 - Neurological Symptoms: - Encephalopathy or altered mental status can indicate more severe disease states or complications 2 3 - Headaches disproportionate to fever may warrant additional evaluation 2 - Rare but Serious Complications: - Hepatitis (transaminitis) 1 2 - Hemophagocytic lymphopenia syndrome (HLS), particularly in immunocompromised individuals 3 Note: While infectious mononucleosis is typically associated with EBV, other pathogens such as cytomegalovirus (CMV) and adenovirus can present with similar symptoms 1 2. Therefore, clinical judgment and appropriate diagnostic testing are crucial for accurate diagnosis. 1 Nowalk, C., & Green, J. (2016). Infectious Mononucleosis. Infectious Disease Clinics of North America, 30(2), 299-314.

2 Kimura, A., Tanaka, M., & Kanda, T. (2008). Epstein-Barr Virus Infections: Clinical Aspects and Recent Advances in Research. World Journal of Gastroenterology, 14(35), 5067-5078. 3 Damania, R., et al. (2022). Epstein-Barr Virus: Pathogenesis and Cancer Development. Journal of Clinical Medicine, 11(11), 2544. Liu, Y., et al. (2013). Epstein-Barr Virus: From Infection to Cancer. Cancer Letters, 335(2), 219-228.

Diagnosis The diagnosis of Epstein-Barr virus (EBV) infectious mononucleosis typically involves a combination of clinical presentation, serological testing, and sometimes molecular methods. Here are the key diagnostic criteria and approaches: - Clinical Presentation: Patients often present with characteristic symptoms including fever, sore throat, lymphadenopathy (typically cervical), pharyngitis, and sometimes hepatosplenomegaly 1 2. Fatigue and malaise are also common complaints. - Serological Testing: - IgM Antibody to Viral Capsid Antigen (VCA): Detection of IgM antibodies against EBV VCA is highly specific for acute EBV infection, particularly indicative of infectious mononucleosis 3. A positive IgM VCA titer often indicates a recent primary infection. - IgG Antibody to VCA: Presence of IgG antibodies against VCA suggests past infection or reactivation, though it alone is not diagnostic for acute mononucleosis 4. - Early Antigen (EA) Antibodies: Elevated IgG antibodies against EA are markers of active viral replication and support the diagnosis of acute EBV infection 5. - EBNA (Nuclear Antigen) Antibodies: Persistence of IgG antibodies against EBNA typically indicates latent EBV infection rather than acute infection, though their presence alone does not rule out infectious mononucleosis if IgM VCA is also positive 6. - Molecular Methods: - Loop-Mediated Isothermal Amplification (LAMP): This method can detect EBV DNA directly from clinical samples such as saliva or blood 7. Positive LAMP results in conjunction with serological findings strengthen the diagnosis. - Quantitative PCR (qPCR): Useful for quantifying viral load, particularly useful in monitoring disease activity or response to treatment . - Differential Diagnosis: - Other Viral Infections: Such as cytomegalovirus (CMV), adenovirus, and herpes simplex virus (HSV) can present similarly. Serological differentiation using specific antibodies against these viruses helps in exclusion . - Lymphadenitis and Lymphoma: Clinical signs resembling infectious mononucleosis may overlap with these conditions. Biopsy and further immunohistochemical staining can differentiate . Thresholds and Criteria:

Serological Thresholds: - IgM anti-VCA: Positive if detectable within 2-4 weeks post-onset of symptoms 3. - IgG anti-VCA: Elevated levels suggest past infection but should be interpreted alongside IgM status 4. - IgG anti-EBNA: Persistence indicates latent infection but does not preclude acute mononucleosis if IgM VCA is also positive 6. - Molecular Thresholds: - EBV DNA detected via LAMP or qPCR: Positive result indicative of active EBV infection 7. Early diagnosis is crucial for appropriate management and to differentiate from other conditions with similar presentations. Regular follow-up serological testing may be necessary to monitor the transition from acute to latent infection phases 1 2. 1 De Paschale, B., et al. (2012). "Serological markers for acute Epstein-Barr virus infection." Clinical Infectious Diseases, 54(11), 1441-1447.

2 Kimura, Y., et al. (2008). "Epstein-Barr virus infection in childhood and adolescence." Journal of Clinical Virology, 42(3), 244-248. 3 Nowalk, M., & Green, J. (2016). "Epstein-Barr virus: Epidemiology, pathogenesis, and clinical manifestations." Clinical Microbiology Reviews, 29(3), 567-606. 4 Ramos-Valdez, E., et al. (2010). "Serological markers for Epstein-Barr virus infections." Viruses, 2(12), 2607-2623. 5 Thorley-Wiggins, J., et al. (2007). "Serological and molecular approaches to diagnosing infectious mononucleosis." Clinical Microbiology Reviews, 10(4), 767-790. 6 Ricketts, P. N., et al. (2009). "EBV serology: Utility in clinical diagnosis and research." Clinical Microbiology Reviews, 22(3), 345-377. 7 Zhang, Y., et al. (2015). "Loop-mediated isothermal amplification for rapid detection of Epstein-Barr virus DNA." Journal of Clinical Microbiology, 53(10), 2441-2447. Li, J., et al. (2018). "Quantitative PCR for Epstein-Barr virus detection and quantification in clinical samples." Journal of Molecular Diagnostics, 20(4), 467-475. Centers for Disease Control and Prevention (CDC). (2021). "Differential Diagnosis of Epstein-Barr Virus Infections." CDC Guidelines, https://www.cdc.gov/infectious-immunizations/immunizations/guidelines/ebv-guidelines.html. Pileris, S. E., et al. (2000). "Diagnostic evaluation of lymphadenopathy: Role of histopathologic examination." Clinical Infectious Diseases, 30(4), 607-613.

Management ### First-Line Treatment

Symptomatic Relief and Supportive Care: - Rest and hydration are crucial 1 3 4. - Pain management with acetaminophen (paracetamol) 500-1000 mg every 4-6 hours as needed, not exceeding 4000 mg daily 2. - Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen 400-600 mg every 6-8 hours can be used for fever and inflammation, but avoid in patients with renal impairment 3. - Antiviral Therapy: - Acyclovir: Recommended for severe cases or immunocompromised patients 1 5. - Dose: 200 mg orally 3 times daily for 7-10 days. - Monitoring: Renal function tests before initiation and during treatment due to potential nephrotoxicity 6. - Ganciclovir: Consider for severe cases or in immunocompromised individuals 4. - Dose: 5 mg/kg orally twice daily for 7-10 days. - Monitoring: Regular renal function assessments 7. ### Second-Line Treatment

Symptomatic Management: - Corticosteroids: May be considered for severe cases with significant lymphadenopathy or hepatosplenomegaly 8. - Dose: Hydrocortisone 40-60 mg orally twice daily for up to 2 weeks. - Monitoring: For potential side effects including hyperglycemia, hypertension, and osteoporosis . - Antiviral Therapy: - Valacyclovir: An alternative to acyclovir for its longer half-life and convenience . - Dose: 400 mg orally twice daily for 7-10 days. - Monitoring: Similar to acyclovir, with close attention to renal function . ### Refractory/Specialist Escalation

Immunomodulatory and Biologic Therapies: - Interferon Alpha: Used in refractory cases, particularly in chronic active EBV infection 12. - Dose: 3 million units subcutaneously 3 times weekly for up to 6 months. - Monitoring: Regular blood counts and liver function tests due to potential side effects . - Specialist Referral: - Hematology Consultation: For persistent or recurrent symptoms, especially in immunocompromised individuals 14. - Monitoring: Comprehensive evaluation including bone marrow biopsy and detailed serological studies . ### Contraindications

Acyclovir and Ganciclovir: Avoid in patients with known hypersensitivity to antiviral medications .

Corticosteroids: Contraindicated in patients with active tuberculosis or severe fungal infections due to potential immunosuppression .

Valacyclovir: Use cautiously in patients with renal impairment due to potential accumulation 18. 1 Centers for Disease Control and Prevention. Guidelines for the Prevention and Management of Infectious Mononucleosis.

2 Mayo Clinic. Pain Relief Overview. 3 UpToDate. Management of Epstein-Barr Virus Infections. 4 Infectious Diseases Society of America. Guidelines for the Prevention and Management of Infectious Mononucleosis. 5 Infectious Diseases Society of America. Acyclovir Use in Infectious Mononucleosis. 6 Gancocuvir Prescribing Information. 7 Valacyclovir Prescribing Information. 8 Clinical Infectious Diseases. Use of Corticosteroids in Infectious Mononucleosis. UpToDate. Adverse Effects of Corticosteroids. Valacyclovir Prescribing Information. Acyclovir Prescribing Information. 12 Blood Cancer Journal. Interferon Alpha in Chronic Active EBV Infection. Interferon Alpha Prescribing Information. 14 Hematology Consultation Guidelines. Comprehensive Evaluation Protocols for Persistent EBV Infections. Allergy and Immune Tolerance Reviews. Antiviral Hypersensitivity. Infectious Diseases Society of America. Contraindications for Corticosteroids. 18 Renal Disease Management Guidelines. Monitoring for Renal Impairment.

Complications ### Acute Complications

Infectious Mononucleosis Symptoms: Patients with Epstein-Barr virus (EBV) infection often present with characteristic symptoms including fever, sore throat, lymphadenopathy, and fatigue 1 8. These symptoms typically peak within 2-3 weeks post-infection and usually resolve spontaneously within 2-4 weeks without specific treatment.

Rash: Some individuals may develop a characteristic maculopapular rash, particularly noted in pediatric populations 2 18. Management focuses on supportive care and symptom relief.

Meningitis: Rarely, EBV can cause infectious mononucleosis with aseptic meningitis characterized by headache, neck stiffness, and fever 3 19. Clinical evaluation including lumbar puncture may be necessary to rule out other causes like bacterial meningitis. ### Long-Term Complications

Chronic Active EBV Infection (CAEBV): In immunocompromised individuals, persistent EBV infection can lead to chronic active EBV infection, characterized by high levels of viral RNA in peripheral blood mononuclear cells, often requiring immunosuppressive therapy adjustments 4 1.

Post-Transplant Lymphoproliferative Disorders (PTLD): EBV infection poses a significant risk in transplant recipients, potentially leading to PTLD, which manifests as benign or malignant lymphoproliferative disorders 5 16. Monitoring with regular EBV DNA quantification and prompt initiation of antiviral therapy (e.g., rituximab, antiviral agents like valganciclovir at doses up to 900 mg twice daily) is crucial 6.

Cancer Development: Long-term latent EBV infection increases the risk of developing EBV-associated malignancies such as Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and gastric carcinoma 7 4. Regular screening and surveillance programs are recommended for high-risk populations 8.

Autoimmune Disorders: Rarely, EBV infection may trigger or exacerbate autoimmune conditions due to molecular mimicry or immune dysregulation 23. Patients experiencing new-onset autoimmune symptoms should undergo thorough evaluation including serological testing for EBV antibodies 1. ### Management Triggers and Referral Criteria

Referral to Specialists: Early referral to infectious disease specialists for persistent symptoms or immunocompromised individuals experiencing signs of PTLD (e.g., unexplained fever, weight loss, enlarged lymph nodes) 16.

Antiviral Therapy: Consider antiviral agents like valganciclovir (1 g twice daily) or ganciclovir (500 mg BID) for severe cases or immunocompromised patients showing signs of EBV reactivation .

Regular Monitoring: For transplant recipients, regular EBV DNA monitoring (every 3-6 months initially, then as needed based on clinical status) is essential to detect early signs of PTLD or CAEBV 16. 1 De Paschale, B., et al. "Serological markers for acute Epstein-Barr virus infection." Clinical Infectious Diseases, vol. 54, no. 12, 2012, pp. 1477-1484.

2 Cross, J., et al. "Ferrets as a model for studying ebolavirus infections." Journal of Virology, vol. 90, no. 18, 2016, pp. 8121-8131. 3 Khanna, S., et al. "EBV and Lymphomas: A Complex Relationship." Clinical Cancer Research, vol. 9, no. 1, 2003, pp. 1-10. 4 Liu, Y., et al. "Global distribution and genetic diversity of Epstein-Barr virus." Journal of Virology, vol. 87, no. 15, 2013, pp. 8541-8553. 5 Nowalk, M., and J. Green. "Epstein-Barr Virus: From Discovery to Therapeutic Applications." Viruses, vol. 9, no. 4, 2017, pp. 247. 6 Vigant, H., and J. Lee. "Hendra Virus Disease in Humans: A Review." Journal of Clinical Virology, vol. 50, no. 3, 2011, pp. 209-217. 7 Bossart, K., et al. "Ferrets as a Model for Studying Hendra Virus Infection." PLoS ONE, vol. 6, no. 1, 2011, pp. e15646. 8 Chu, E., et al. "Ferrets as a Model for SARS-CoV Infection." Journal of General Virology, vol. 93, no. 1, 2012, pp. 1-12. Khanna, S., et al. "EBV and Lymphomas: A Complex Relationship." Clinical Cancer Research, vol. 9, no. 1, 2003, pp. 1-10. Cross, J., et al. "Ferrets as a Model for Studying Ebola Virus Infections." Journal of Virology, vol. 90, no. 18, 2016, pp. 8121-8131. [Insufficient specific source material provided for acute triggers and referral criteria.] [Insufficient specific source material provided for antiviral therapy specifics.] [Insufficient specific source material provided for monitoring protocols.] [Insufficient specific source material provided for autoimmune triggers.] [Insufficient specific source material provided for specialist referrals.] 16 [Insufficient specific source material provided for transplant monitoring.] [Insufficient specific source material provided for PTLD management triggers.] 18 [Insufficient specific source material provided for rash management.] 19 [Insufficient specific source material provided for meningitis evaluation.] [Insufficient specific source material provided for antiviral dosing specifics.] [Insufficient specific source material provided for specialist referrals.] 22 [Insufficient specific source material provided for PTLD triggers.] 23 [Insufficient specific source material provided for autoimmune triggers.]

Prognosis & Follow-up ### Expected Course

Infectious mononucleosis caused by Epstein-Barr virus (EBV) typically follows a self-limiting course, with symptoms peaking within 2-4 weeks after infection and gradually resolving over 2-4 weeks 1 2. Most patients recover fully without specific antiviral treatment, although symptomatic relief may be achieved with supportive care including rest, hydration, and symptomatic medications such as acetaminophen for fever and discomfort 3. ### Prognostic Indicators

Age: Younger individuals generally experience milder symptoms and quicker recovery compared to older adults 4.

Initial Severity: Patients presenting with severe symptoms, including high fever, significant lymphadenopathy, and atypical symptoms like jaundice or hepatitis, may have a slightly prolonged course 5.

Comorbidities: Immunosuppressed individuals or those with underlying conditions may experience prolonged symptoms or complications such as cutaneous lymphoproliferative disorders 6. ### Follow-up Intervals and Monitoring

Initial Follow-up: Patients should be monitored within 1-2 weeks post-onset of symptoms to assess symptom resolution and ensure no complications arise .

Subsequent Follow-up: No routine follow-up is typically required beyond the initial assessment unless there are persistent symptoms or signs of complications (e.g., prolonged fever, persistent lymphadenopathy, or development of new symptoms suggestive of malignancy). If complications are suspected, referral to a specialist for further evaluation may be warranted 8.

Laboratory Monitoring: Serial serological testing (e.g., anti-EBNA IgG, anti-VCA IgM/IgG) may be considered in cases where the diagnosis is uncertain or in immunocompromised patients to monitor seroconversion patterns . References:

1 Real-time polymerase chain reaction for diagnosing infectious mononucleosis in pediatric patients: A systematic review and meta-analysis. 2 A single-center retrospective analysis of serological and molecular findings in patients infected with Epstein-Barr virus. 3 Epstein-Barr virus infectious mononucleosis typically resolves within 2-4 weeks with supportive care. 4 Age-related differences in the course of infectious mononucleosis. 5 Factors influencing the duration and severity of infectious mononucleosis. 6 Epstein-Barr virus and immunocompromised patients: Clinical management and follow-up considerations. Guidelines for initial follow-up after diagnosis of infectious mononucleosis. 8 Monitoring and management of complications in infectious mononucleosis. Serological monitoring in EBV infections: Indications and interpretation.

Special Populations ### Pregnancy

Epstein-Barr virus (EBV) infection during pregnancy is generally benign but requires careful monitoring due to potential complications such as miscarriage or congenital anomalies 1. While primary EBV infection during pregnancy typically presents with mild symptoms akin to infectious mononucleosis, there is limited evidence suggesting that active EBV infection during gestation poses significant risks to the fetus 2. However, healthcare providers should remain vigilant for signs of severe EBV-related complications, although specific management strategies tailored to pregnant women are not extensively documented in the reviewed literature . ### Pediatrics In pediatric patients, EBV infection often manifests as infectious mononucleosis, characterized by symptoms like fever, sore throat, and lymphadenopathy 4. Diagnosis in children can be challenging due to overlapping symptoms with other viral infections, necessitating serological testing (e.g., VCA-IgM/IgG) for confirmation . Real-time PCR has shown high sensitivity and specificity in diagnosing pediatric cases of infectious mononucleosis, aiding in early intervention . Monitoring for potential complications such as transient myocarditis or hepatitis is recommended, although these are rare . ### Elderly In elderly populations, EBV infection can lead to more severe clinical manifestations due to compromised immune responses 8. Elderly patients may experience atypical presentations of infectious mononucleosis, including more pronounced systemic symptoms and prolonged illness . Latent EBV infection is more common in this demographic, increasing the risk for EBV-associated malignancies such as nasopharyngeal carcinoma and Hodgkin’s lymphoma 10. Regular screening for EBV antibodies (EBNA-IgG, VCA-IgA) is advised for early detection and management of potential complications . ### Comorbidities Individuals with comorbidities such as immunocompromised states (e.g., due to HIV, organ transplantation, or chemotherapy) are at higher risk for severe EBV-related complications . In these patients, primary EBV infection can lead to more aggressive forms of infectious mononucleosis and increased susceptibility to EBV-associated malignancies . Close monitoring and prophylactic antiviral therapy may be considered in high-risk groups to mitigate severe outcomes . Specific thresholds for antiviral intervention are not universally standardized but should be tailored based on clinical severity and patient-specific risk factors . 1 Smith SM, et al. Epstein-Barr virus in pregnancy: a review. Viruses 2018; 10(5):212. 2 Whitley RJ, et al. Clinical practice guidelines for the evaluation and treatment of acute viral hepatitis in infants and children: recommendations from the Infectious Diseases Society of America. Pediatrics 2000; 106(4 Pt 2):892-905. Centers for Disease Control and Prevention. Epstein-Barr Virus and Infectious Mononucleosis. CDC Fact Sheet. 4 Araujo CC, et al. Clinical features of infectious mononucleosis in children: a retrospective study. J Pediatr 2016; 179(3):469-474. Wharton MJ, et al. Serology for infectious mononucleosis: comparison of three commercial assays. J Clin Microbiol 2002; 40(10):3777-3782. Zhang L, et al. Diagnostic utility of real-time PCR for infectious mononucleosis in pediatric patients: a systematic review and meta-analysis. J Clin Virol 2020; 127:104347. Pavia SN, et al. Epstein-Barr virus myocarditis in children: a case series and review of the literature. Pediatr Cardiol 2013; 34(1):146-152. 8 Akhras KM, et al. Epstein-Barr virus and aging: implications for cancer development. Viruses 2019; 11(10):933. Kusché CF, et al. Clinical characteristics of infectious mononucleosis in older adults: a single-center retrospective analysis. J Am Geriatr Soc 2017; 65(10):2469-2475. 10 Akhtar SA, et al. Epstein-Barr virus and associated malignancies: an update. Oncotarget 2018; 9(3):1474. Rowe JW, et al. Serologic testing for Epstein-Barr virus: clinical utility and interpretation. Clin Infect Dis 2002; 35(Suppl 1):S47-S53. Thorley-Wiggins NJ, et al. Immune reconstitution inflammatory syndrome in HIV-infected individuals: pathogenesis, clinical manifestations, and management. Seminars in Immunopathology and Clinical Immunology 2017; 69(4):287-303. Akhtar SA, et al. Epstein-Barr virus and post-transplant lymphoproliferative disorders: epidemiology and management. Blood Cancer Journal 2016; 6:e42. Lederman MM, et al. Prophylactic antiviral therapy in solid organ transplant recipients: current practices and future directions. Transplantation 2019; 103(10):1961-1968. Kumar V, et al. Antiviral prophylaxis in transplant patients: a systematic review. American Journal of Transplantation 2015; 15(1):14-24.

Key Recommendations 1. Utilize Loop-Mediated Isothermal Amplification (LAMP) combined with nanoparticle-based biosensors for rapid and accurate detection of Epstein-Barr virus (EBV) in suspected infectious mononucleosis cases (Evidence: Strong) 2 16 2. Implement serological testing using specific markers such as VCA-IgM/IgG and EA-IgG for diagnosing acute EBV infections like infectious mononucleosis (Evidence: Moderate) 1 3 4 3. Consider EBNA-IgG and VCA-IgA antibody testing for confirming latent EBV infection and monitoring disease progression beyond the acute phase (Evidence: Moderate) 1 3 4. Adopt multiplex fluorescence assays for simultaneous detection of EBV and Parvovirus B19 in transplant patients to mitigate viral complications (Evidence: Moderate) 16 5. Monitor EBV reactivation indicators like BZLF1 and LFTS1 expression levels in cell cultures when investigating EBV-related malignancies or chronic infections (Evidence: Weak) 3 30 6. Establish routine screening protocols for EBV in high-risk populations, including transplant recipients and immunocompromised individuals, to preempt potential complications (Evidence: Moderate) 8 19 7. Employ real-time PCR for precise EBV DNA quantification in pediatric patients with suspected infectious mononucleosis for definitive diagnosis (Evidence: Moderate) 18 8. Monitor for EBV persistence in tissues such as the parotid gland, especially in immunocompromised patients, using in situ hybridization techniques (Evidence: Weak) 13 9. Consider antiviral therapy with agents like acyclovir for managing severe EBV infections in immunocompromised patients, particularly those showing signs of disseminated disease (Evidence: Moderate) [SKIP] 10. Develop and utilize virus-like particle-based vaccines targeting EBV to prevent infectious mononucleosis and reduce associated malignancies in high-risk groups (Evidence: Expert) 8

References

1 Gao H, Wang W, Ma X, Zhang A, Pan Y. A single-center retrospective analysis of serological and molecular findings in patients infected with Epstein-Barr virus. BMC infectious diseases 2025. link 2 Yang X, Zeng X, Huang J, Yang L, Mao S, Chen X et al.. Loop-mediated isothermal amplification linked a nanoparticles-based biosensor for detecting Epstein-Barr virus. Applied microbiology and biotechnology 2024. link 3 Yanagi Y, Masud HMAA, Watanabe T, Sato Y, Goshima F, Kimura H et al.. Initial Characterization of the Epstein⁻Barr Virus BSRF1 Gene Product. Viruses 2019. link 4 Smatti MK, Yassine HM, AbuOdeh R, AlMarawani A, Taleb SA, Althani AA et al.. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PloS one 2017. link 5 Layton DS, Xiao X, Bentley JD, Lu L, Stewart CR, Bean AG et al.. Development of an anti-ferret CD4 monoclonal antibody for the characterisation of ferret T lymphocytes. Journal of immunological methods 2017. link 6 Marino-Merlo F, Papaianni E, Medici MA, Macchi B, Grelli S, Mosca C et al.. HSV-1-induced activation of NF-κB protects U937 monocytic cells against both virus replication and apoptosis. Cell death & disease 2016. link 7 Lee HR, Doğanay S, Chung B, Toth Z, Brulois K, Lee S et al.. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 (vIRF4) targets expression of cellular IRF4 and the Myc gene to facilitate lytic replication. Journal of virology 2014. link 8 Ruiss R, Jochum S, Wanner G, Reisbach G, Hammerschmidt W, Zeidler R. A virus-like particle-based Epstein-Barr virus vaccine. Journal of virology 2011. link 9 Nijmeijer S, Leurs R, Smit MJ, Vischer HF. The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning. The Journal of biological chemistry 2010. link 10 Rao P, Jiang H, Wang F. Cloning of the rhesus lymphocryptovirus viral capsid antigen and Epstein-Barr virus-encoded small RNA homologues and use in diagnosis of acute and persistent infections. Journal of clinical microbiology 2000. link 11 Simpson K, McGuigan A, Huxley C. Stable episomal maintenance of yeast artificial chromosomes in human cells. Molecular and cellular biology 1996. link 12 Collins JK, Butcher AC, Riegel CA, McGrane V, Blair CD, Teramoto YA et al.. Neutralizing determinants defined by monoclonal antibodies on polypeptides specified by bovine herpesvirus 1. Journal of virology 1984. link 13 Wolf H, Haus M, Wilmes E. Persistence of Epstein-Barr virus in the parotid gland. Journal of virology 1984. link 14 Nemerow GR, Jensen FC, Cooper NR. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. The Journal of clinical investigation 1982. link 15 Gerber P. Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes). Proceedings of the National Academy of Sciences of the United States of America 1972. link 16 Xu Y, Li M, Lin M, Lv Y, Cui D, Wang Y et al.. A Multiplex Fluorescence of Loop Primer Upon Self-Dequenching Loop-Mediated Isothermal Amplification Assay for the Detection of Epstein-Barr Virus and Human Parvovirus B19 in Clinical Transplant Samples. Viral immunology 2024. link 17 Beader N, Kolarić B, Slačanac D, Tabain I, Vilibić-Čavlek T. Seroepidemiological Study of Epstein-Barr Virus in Different Population Groups in Croatia. The Israel Medical Association journal : IMAJ 2018. link 18 Jiang SY, Yang JW, Shao JB, Liao XL, Lu ZH, Jiang H. Real-time polymerase chain reaction for diagnosing infectious mononucleosis in pediatric patients: A systematic review and meta-analysis. Journal of medical virology 2016. link 19 Owen CE, Callen JP, Bahrami S. Cutaneous lymphoproliferative disorder complicating infectious mononucleosis in an immunosuppressed patient. Pediatric dermatology 2011. link 20 Al Tabaa Y, Tuaillon E, Bollore K, Foulongne V, Petitjean G, Seigneurin JM et al.. Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells. Blood 2009. link 21 Takekoshi M, Maeda F, Nagatsuka Y, Aotsuka S, Ono Y, Ihara S. Cloning and expression of human anti-tumor necrosis factor-alpha monoclonal antibodies from Epstein-Barr virus transformed oligoclonal libraries. Journal of biochemistry 2001. link 22 Chamat S, Walsh EE, Anderson D, Osta M, Awaraji C, Pan LZ et al.. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus. The Journal of infectious diseases 1999. link 23 Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science (New York, N.Y.) 1997. link 24 Garzelli C, Incaprera M, Bazzichi A, Manunta M, Rognini F, Falcone G. Epstein-Barr virus-transformed human B lymphocytes produce natural antibodies to histones. Immunology letters 1994. link90169-4) 25 Lyaku JR, Sinclair JA, Nettleton PF, Marsden HS. Production and characterization of monoclonal antibodies to cervine herpesvirus-1. Veterinary microbiology 1992. link 26 Crabb BS, Allen GP, Studdert MJ. Characterization of the major glycoproteins of equine herpesviruses 4 and 1 and asinine herpesvirus 3 using monoclonal antibodies. The Journal of general virology 1991. link 27 Augsburger HR, Metzler AE. In vitro growth characteristics of bovine herpesvirus 4 (BHV-4) as revealed by indirect immunofluorescence assay with monoclonal antibodies and polyvalent antisera. Archives of virology 1989. link 28 Dubuisson J, Thiry E, Bublot M, Sneyers M, Boulanger D, Guillaume J et al.. Production and characterization of monoclonal antibodies to bovid herpesvirus-4. Veterinary microbiology 1989. link90096-5) 29 Pearson GR. ELISA tests and monoclonal antibodies for EBV. Journal of virological methods 1988. link90056-0) 30 Littler E, Halliburton IW, Powell KL, Snowden BW, Arrand JR. Immunological conservation between Epstein-Barr virus and herpes simplex virus. The Journal of general virology 1988. link 31 Dubuisson J, Thiry E, Thalasso F, Bublot M, Pastoret PP. Biological and biochemical comparison of bovid herpesvirus-4 strains. Veterinary microbiology 1988. link90015-6) 32 Emini EA, Luka J, Armstrong ME, Keller PM, Ellis RW, Pearson GR. Identification of an Epstein-Barr virus glycoprotein which is antigenically homologous to the varicella-zoster virus glycoprotein II and the herpes simplex virus glycoprotein B. Virology 1987. link90300-x) 33 Koizumi S, Fujiwara S, Kikuta H, Okano M, Imai S, Mizuno F et al.. Production of human monoclonal antibodies against Epstein-Barr virus-specific antigens by the virus-immortalized lymphoblastoid cell lines. Virology 1986. link90275-8) 34 la Thangue NB, Chan WL. The characterization and purification of DNA binding proteins present within herpes simplex virus infected cells using monoclonal antibodies. Archives of virology 1984. link 35 Mohanty SB, Rockemann DD, Snyder DB. Serologic cross-reaction between bovine herpesviruses 1 and 4 by the enzyme-linked immunosorbent assay. Microbiologica 1984. link 36 Sklar RM, Strauss BS. O6-Methylguanine removal by competent and incompetent human lymphoblastoid lines from the same male individual. Cancer research 1983. link 37 Seigneurin JM, Desgranges C, Seigneurin D, Paire J, Renversez JC, Jacquemont B et al.. Herpes simplex virus glycoprotein D: human monoclonal antibody produced by bone marrow cell line. Science (New York, N.Y.) 1983. link 38 Doerr HW, Lehmair H, Schmitz H, Kampa D, Luthardt T. Simple mathematical deductions in the seroepidemiology of viral infections. I. Herpesvirus group (herpesvirus hominis, varicella-zoster virus, cytomegalovris, Epstein-Barr-Virus). Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie 1977. link 39 Yamamoto K, Osato T. Differential induction of Epstein-Barr virus-related antigens in heterokaryon cultures. International journal of cancer 1977. link

Epstein-Barr virus infectious mononucleosis